Nebulized Tranexamic Acid in Sinus Surgery

Launched by ASSIUT UNIVERSITY · May 24, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called nebulized tranexamic acid during sinus surgery to see if it can help reduce bleeding and improve the overall experience for both surgeons and patients. Tranexamic acid is a drug that can help with bleeding issues, and researchers want to find out the best and safest dose to use during this type of surgery.

To be part of this trial, participants need to be adults aged 18 to 65 who are scheduled for elective functional endoscopic sinus surgery (a common type of sinus surgery) and are generally healthy. They should also have normal blood clotting ability and a certain level of red blood cells. However, people with certain health conditions, such as severe kidney or liver problems, bleeding disorders, or those taking specific blood-thinning medications, won't be eligible to join. If you participate, you can expect to receive nebulized tranexamic acid during your surgery, and the results will help doctors understand how well it works and how it can be used safely in future procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Either sexes (age 18-65 years) of ASA I-II who are listed for elective functional endoscopic sinus surgery (FESS) under general anesthesia
• • normal accepted coagulation profile and hematocrit value ≥30
• Exclusion Criteria:
• • chronic renal failure
• • liver cirrhosis
• • bleeding disorders
• • current anticoagulant therapy
• • pregnancy or breastfeeding
• • impaired color vision
• • severe vascular ischemia
• • history of venous thrombosis, pulmonary embolism
• • long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery
• • hemoglobin (HB) concentration \<10 mg/dl _allergy to TXA.